Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Articles

Page 1 of 19

  1. The treatment of choice for substance use disorder (SUD) caused by sedatives, hypnotics, and anxiolytics (SHA) is to slowly taper the dose of the implicated substance to the point of abstinence, thereby minimi...

    Authors: Philipp Pauwels, Beatrice Haack, Sermin Toto, Johanna Seifert, Renate Grohmann, Martin Heinze, Oliver Zolk, Phileas Johannes Proskynitopoulos, Michael Schneider and Timo Greiner
    Citation: Addiction Science & Clinical Practice 2025 20:51
    Content type: Research Published on:

  2. For people with opioid use disorder (OUD), extended-release naltrexone (XR-NTX) is an effective antagonist treatment option. However, successful opioid tapering and abstinence is a prerequisite for XR-NTX indu...

    Authors: Jon Mordal, Farid Juya, Line Holtan, John-Kåre Vederhus, Arild Opheim, Ida H. Brenna, Asle E. Enger, Bente Weimand, Kristin Klemmetsby Solli and Lars Tanum
    Citation: Addiction Science & Clinical Practice 2025 20:50
    Content type: Research Published on:

  3. Substance use disorder (SUD) is a growing public health concern in Sweden. Various treatments for SUD exist, with motivational treatment, cognitive behavioral therapy, and relapse prevention being the national...

    Authors: Nóra Kerekes, Kourosh Bador, Carro Smedeby, Linus Hansen, Sofie Lundström and Monica Eriksson
    Citation: Addiction Science & Clinical Practice 2025 20:49
    Content type: Research Published on:

  4. Contingency management (CM) that is delivered by peer recovery support specialists and incentivizes harm reduction goals among people not seeking treatment for stimulant use has not been tested. The Peers Expa...

    Authors: Alexis Cooke, Erin Stack, Linda Peng, Ryan Cook, Bryan Hartzler, Gillian Leichtling, Christi Hildebran, Judith M. Leahy, Kelsey Smith Payne, Lynn E. Kunkel, Kim Hoffman and P. Todd Korthuis
    Citation: Addiction Science & Clinical Practice 2025 20:48
    Content type: Study Protocol Published on:

  5. High-risk opioid prescribing (e.g., high daily dose opioids, concurrent opioid-sedatives) is prevalent in hospitals and linked to adverse outcomes. Opioid stewardship programs (OSP) have the potential to reduc...

    Authors: Lianping Ti, Tamara Mihic, Arielle Beauchesne, Cameron Grant, Ingrid Frank, Nooreen Haji, Michael Legal, Stephen Shalansky and Seonaid Nolan
    Citation: Addiction Science & Clinical Practice 2025 20:47
    Content type: Research Published on:

  6. Just-In-Time Adaptive Interventions (JITAIs) offer real-time support to help individuals adhere to gambling expenditure goals. This mixed-methods study evaluated the acceptability of a JITAI called Gambling Habit...

    Authors: S. N. Rodda, S. S. Merkouris, C. J. Greenwood, A. C. Thomas, D. I. Lubman and N. A. Dowling
    Citation: Addiction Science & Clinical Practice 2025 20:46
    Content type: Research Published on:

  7. E-cigarettes may serve as a safer alternative to combustible cigarettes and may be more effective than currently available nicotine replacement therapy (NRT). Little is known about the perceptions of using e-c...

    Authors: Sidney V Rojas, Kelly A. Kyanko, Rachel Wisniewski, Katherine O’Connor, Rina Li, Grace Xiang, Mahathi Vojjala, Olivia Wilker, Scott E. Sherman and Elizabeth R. Stevens
    Citation: Addiction Science & Clinical Practice 2025 20:45
    Content type: Research Published on:

  8. This sub-analysis of the PROPDESC-study (Pre-Operative Prediction of postoperative delirium by appropriate Screening-study) evaluated the alcohol consumption of older patients with two different assessment too...

    Authors: Vera Guttenthaler, Maria Wittmann and Jan Menzenbach
    Citation: Addiction Science & Clinical Practice 2025 20:44
    Content type: Research Published on:

  9. Excessive alcohol consumption is a significant global health issue, often unaddressed in primary care. The 15-method, a three-step opportunistic screening and treatment tool premised on Motivational Interviewi...

    Authors: Peter Næsborg Schøler, Jens Søndergaard, Sanne Rasmussen, Kristina Hasselbalch Volke, Per Nilsen and Anette Søgaard Nielsen
    Citation: Addiction Science & Clinical Practice 2025 20:43
    Content type: Research Published on:

  10. Buprenorphine is a common partial opioid agonist treatment for opioid use disorder (OUD). Despite its efficacy, major challenges to induction include the significant time consumption and the difficult requirem...

    Authors: Pouya Azar, Jessica Machado, Jane J. Kim, James S. H. Wong, Mohammadali Nikoo and Victor W. Li
    Citation: Addiction Science & Clinical Practice 2025 20:42
    Content type: Case Report Published on:

  11. Every year about three million people die globally due to harmful alcohol use. The treatment gap remains high: only about 14% of individuals with problematic alcohol use access treatment. The implementation of...

    Authors: Elisabeth Petersén, Hanna Augustsson Öfverström, Magnus Johansson, Christopher Sundström and Anne H. Berman
    Citation: Addiction Science & Clinical Practice 2025 20:41
    Content type: Research Published on:

  12. Cocaine and methamphetamine use disorders (CcUD/MtUD) have serious public health, medical, and psychiatric consequences. Yet, there are no U.S. Food and Drug Administration (FDA) approved treatments available....

    Authors: Zahraa Atoui, Donald Egan, Manish Kumar Jha, Karen Hartwell, Russell Toll, Susan Sonne, Brenda Brunner-Jackson, Geetha Subramaniam, Jenna L. McCauley, Madhukar Trivedi and Kathleen Brady
    Citation: Addiction Science & Clinical Practice 2025 20:40
    Content type: Methodology Published on:

  13. Opioid use disorder often co-occurs with other mental health and substance use disorders. Identifying clusters of individuals receiving treatment for opioid use disorder based on co-diagnosed conditions, healt...

    Authors: Orrin D. Ware, Jamey J. Lister, Sarah E. Cooper, Andrew H. Kim, Holly H. Lister, N. Andrew Peterson, Stephen Fioravanti, Kristen Gilmore Powell, Stephanie C. Marcello and Bethany Joseph
    Citation: Addiction Science & Clinical Practice 2025 20:39
    Content type: Research Published on:

  14. Medications for opioid use disorder are evidence-based, guideline-recommended treatments. While buprenorphine can be prescribed in nonspecialized office-based settings, it is underutilized. Using a multifacete...

    Authors: Aline Lott, Anissa N. Danner, Carol A. Malte, Hope A. Salameh, Diana Bachowski, Adam J. Gordon, Hildi J. Hagedorn, Madeline C. Frost, Emily C. Williams, Andrew J. Saxon, Ryan S. Trim and Eric J. Hawkins
    Citation: Addiction Science & Clinical Practice 2025 20:38
    Content type: Research Published on:

  15. Programs that aim to increase access to substance use disorder (SUD) treatment in hospital-based settings have proliferated in recent years. These efforts include transitional opioid programs (TOPs), which nav...

    Authors: Zoe Lindenfeld, Berkeley Franz, Alden Yuanhong Lai, José A. Pagán, Cheyenne Fenstemaker, Cory E. Cronin and Ji Eun Chang
    Citation: Addiction Science & Clinical Practice 2025 20:37
    Content type: Research Published on:

  16. E-cigarette use (i.e., vaping) is prevalent among young adults in the U.S. Studies show that young adults who vape are more likely to initiate cigarette smoking than young adults who do not vape. Despite this,...

    Authors: Denise D. Tran, Jordan P. Davis, Keegan Buch, Adam M. Leventhal, Sarah W. Feldstein Ewing and Eric R. Pedersen
    Citation: Addiction Science & Clinical Practice 2025 20:36
    Content type: Study Protocol Published on:

  17. Longer duration of treatment with medication for opioid use disorder (MOUD) is associated with improved outcomes, but long-term retention remains a challenge. Research is needed to identify psychosocial interv...

    Authors: Emma N. Cleary, Angela L. Rollins, Alan B. McGuire, Laura J. Myers and Patrick D. Quinn
    Citation: Addiction Science & Clinical Practice 2025 20:35
    Content type: Research Published on:

  18. Cue exposure (CE) is used for relapse prevention as part of smoking cessation therapy to reduce the automatized response to smoking-related cues. Using CET in virtual reality (VR) is an approach to increase it...

    Authors: A. M. Kroczek, B. Schröder, D. Rosenbaum, A. Mühleck, J. Diemer, A. Mühlberger, A. C. Ehlis and A. Batra
    Citation: Addiction Science & Clinical Practice 2025 20:34
    Content type: Research Published on:

  19. In response to greater illicit fentanyl use, buprenorphine daily doses exceeding the FDA’s recommended target daily dose (16 mg) and maximum suggested daily dose (24 mg) may provide better outcomes, but little...

    Authors: Bradley D. Stein, Flora Sheng, Brendan K. Saloner, Adam J. Gordon and Jessica S. Merlin
    Citation: Addiction Science & Clinical Practice 2025 20:33
    Content type: Research Published on:

  20. Palliative care focuses on controlling symptoms and improving the patient’s quality of life. To achieve this, medications with addictive potential are often used. There have been various case reports of substa...

    Authors: Jannis Eersink, Julian Maul, Nils Heuser, Astrid Morin, Martin Gschnell and Christian Volberg
    Citation: Addiction Science & Clinical Practice 2025 20:32
    Content type: Research Published on:

  21. Detrimental smoking-related health outcomes warrant the investigation of novel smoking cessation interventions; the cessation program nuumi integrates digital behavioral therapy and an electronic cigarette (EC).

    Authors: Helen Schiek, Tobias Esch and Cosima Hoetger
    Citation: Addiction Science & Clinical Practice 2025 20:31
    Content type: Research Published on:

  22. Insomnia is a common condition experienced by many individuals with excessive alcohol use and alcohol use disorder, and the serotonin antagonist and reuptake inhibitor trazodone has emerged as a mainstay of tr...

    Authors: Jeffrey Pan, Jürgen Rehm and Evan Wood
    Citation: Addiction Science & Clinical Practice 2025 20:30
    Content type: Comment Published on:

  23. Authors: E. Jennifer Edelman, Oscar F. Rojas-Perez, Charla Nich, Joanne Corvino, Tami Frankforter, Derrick Gordon, Ayana Jordan, Manuel Paris, Jr, Melissa B. Weimer, Brian T. Yates, Emily C. Williams and Brian D. Kiluk
    Citation: Addiction Science & Clinical Practice 2025 20:29
    Content type: Correction Published on:

    The original article was published in Addiction Science & Clinical Practice 2023 18:55

  24. The Car, Relax, Alone, Forget, Friends, Trouble (CRAFFT) scale is a widely used screening tool for early identification of alcohol and other drug use, and assessing the risk of substance use disorders in adole...

    Authors: Hicham El Malki, Abdelfettah El-Ammari, Salma Ghofrane Moutawakkil, Samir Elgnaoui, Fatima El Houari, Karima El Rhazi and Btissame Zarrouq
    Citation: Addiction Science & Clinical Practice 2025 20:28
    Content type: Research Published on:

  25. Efforts to scale up overdose education and naloxone distribution (OEND), an evidence-based practice for reducing opioid overdose mortality, was a major focus of the HEALing Communities Study (HCS). The aim of ...

    Authors: Hannah K. Knudsen, Sandra Back-Haddix, Shaquita Andrews-Higgins, Michael Goetz, Olivia A. Davis, Douglas R. Oyler, Sharon L. Walsh and Patricia R. Freeman
    Citation: Addiction Science & Clinical Practice 2025 20:27
    Content type: Research Published on:

  26. An estimated 84,181 people died due to opioid overdose in 2022 alone [1]. Mobile technologies may offer an additional pathway to provide support to people seeking recovery from opioid use disorder (OUD). To this ...

    Authors: Alivia Williamson, Behnam Heydarshahi, Diadora Finley-Abboud, Lili Massac, Lindsay Jacobson, Naicha Christophe, Judeline Joseph, Allison Futter, Susanne S. Hoeppner and Bettina B. Hoeppner
    Citation: Addiction Science & Clinical Practice 2025 20:26
    Content type: Research Published on:

  27. Translating innovative research advancements into commercially viable medical interventions presents well-known challenges. However, there is limited understanding of how specific patient, clinical, social, an...

    Authors: Matthew P. Heshmatipour, Tyler M. Duvernay, Desislava Z. Hite, Eboo Versi, Michael P. Hite, David F. Reeser, Victor Prikhodko, Ariana M. Nelson, Bina Julian and Milton L. Greenberg
    Citation: Addiction Science & Clinical Practice 2025 20:25
    Content type: Research Published on:

  28. Authors: Kevin Y. Xu, Jennifer K. Bello, Joanna Buss, Hendrée E. Jones, Laura J. Bierut, Dustin Stwalley, Hannah S. Szlyk, Caitlin E. Martin, Jeannie C. Kelly, Ebony B. Carter, Elizabeth E. Krans and Richard A. Grucza
    Citation: Addiction Science & Clinical Practice 2025 20:24
    Content type: Correction Published on:

    The original article was published in Addiction Science & Clinical Practice 2025 20:1

  29. Conducting research within a carceral health care context offers a unique view into the nature of drug use among arrestees with potential to identify and prevent drug use consequences. The purpose of this stud...

    Authors: Joseph E. Schumacher, Abdullah Ahsan, Amber H. Simpler, Adam P. Natoli and Bradley J. Cain
    Citation: Addiction Science & Clinical Practice 2025 20:23
    Content type: Research Published on:

  30. Buprenorphine is an effective first-line treatment for opioid use disorder (OUD) that substantially reduces morbidity and mortality. For patients using illicitly-manufactured fentanyl (IMF), however, transitio...

    Authors: Beth E. Williams, Stephen A. Martin, Kim A. Hoffman, Mason D. Andrus, Elona Dellabough-Gormley and Bradley M. Buchheit
    Citation: Addiction Science & Clinical Practice 2025 20:22
    Content type: Research Published on:

  31. Deaths from opioid overdose have increased dramatically in the past decade. For individuals with opioid use disorder (OUD), agonist medications such as methadone and buprenorphine reduce opioid-related morbidi...

    Authors: Melissa Davoust, Angela R. Bazzi, Samantha Blakemore, Juliana Blodgett, Anna Cheng, Sarah Fielman, Kara M. Magane, Jacqueline Theisen, Richard Saitz, Alicia S. Ventura and Zoe M. Weinstein
    Citation: Addiction Science & Clinical Practice 2025 20:21
    Content type: Research Published on:

  33. Public health experts currently agree that heated tobacco products (HTPs) pose a significant health risk for their consumers. The same concentrations and speed of delivery of nicotine found for HTPs and conven...

    Authors: Feten Fekih-Romdhane, Rabih Hallit, Diana Malaeb, Fouad Sakr, Mariam Dabbous, Sahar Obeid and Souheil Hallit
    Citation: Addiction Science & Clinical Practice 2025 20:20
    Content type: Research Published on:

  34. Withdrawal prior to buprenorphine initiation may be intolerable or create barriers to therapy. We aim to update our previous systematic review on the efficacy and safety of buprenorphine initiation strategies ...

    Authors: Kathleen K. Adams, Kristin Waters and Diana M. Sobieraj
    Citation: Addiction Science & Clinical Practice 2025 20:19
    Content type: Review Published on:

  35. Addiction Medicine training in Canada has evolved substantially in the last few years with the establishment of accreditation standards and several new fellowship programs. The novelty of these formal training...

    Authors: Clara Lu, Kathryn Chan, Leslie Martin and Nadia Fairbairn
    Citation: Addiction Science & Clinical Practice 2025 20:18
    Content type: Research Published on:

  36. Little is known regarding predictors of outcome in treatment of alcohol dependence via the internet and in primary care. The aim of the present study was to investigate the role of socio-demographic and clinic...

    Authors: Karin Hyland, Danilo Romero, Sven Andreasson, Anders Hammarberg, Erik Hedman-Lagerlöf and Magnus Johansson
    Citation: Addiction Science & Clinical Practice 2025 20:17
    Content type: Research Published on:

  37. The availability of the fellowships of Alcoholics Anonymous and Narcotics Anonymous in community settings is extensive and patients admitted to treatment programs for substance use disorder may therefore have ...

    Authors: Marc Galanter, William L. White, Michael L. Dennis, Brooke Hunter, Lora Passetti and Dan Lustig
    Citation: Addiction Science & Clinical Practice 2025 20:16
    Content type: Research Published on:

  38. In South Africa, community-oriented primary care teams work to re-engage out-of-care people with HIV (PWH) in treatment, many of whom have substance use (SU) concerns. SU stigma is high among these teams, limi...

    Authors: Bronwyn Myers, Kristen S. Regenauer, Kim Johnson, Imani Brown, Alexandra L. Rose, Nonceba Ciya, Sibabalwe Ndamase, Yuche Jacobs, Morgan S. Anvari, Abigail Hines, Dwayne Dean, Rithika Baskar and Jessica F. Magidson
    Citation: Addiction Science & Clinical Practice 2025 20:15
    Content type: Research Published on:

  39. Individuals with opioid use disorder face barriers accessing first-line pharmacotherapy. Home delivery interventions have been shown to improve medication adherence for other chronic diseases, but the relation...

    Authors: Marlene C. Lira, Lauren E. Hendy, Alisha Liakas, Laura Turanchik, Clare Pritchard, Cynthia Jimes and M. Justin Coffey
    Citation: Addiction Science & Clinical Practice 2025 20:14
    Content type: Correspondence Published on:

  40. Given the opioid overdose crisis, surveillance of evolving opioid use patterns is critical to the effective deployment of mitigation strategies. The National Survey on Drug Use and Health (NSDUH) provided the ...

    Authors: Jarratt D. Pytell, Paul J. Christine, Katherine LeMasters, Karilynn M. Rockhill, Joshua C. Black, Richard C. Dart and Ingrid A. Binswanger
    Citation: Addiction Science & Clinical Practice 2025 20:13
    Content type: Research Published on:

  41. Posttraumatic stress disorder (PTSD) is highly comorbid with substance use disorders (SUDs), resulting in high prevalence of PTSD among individuals in residential SUD care. However, there is limited research o...

    Authors: Natalia Van Doren, Fang-Hsi Chang, Amanda Nguyen, Kevin R. McKenna, Derek D. Satre and Shannon Wiltsey-Stirman
    Citation: Addiction Science & Clinical Practice 2025 20:11
    Content type: Research Published on:

  42. The increase in opioid use disorder among young, nonurban people has fueled sharp rises in hepatitis C virus (HCV) infections. Innovative treatment models are needed that circumvent healthcare system barriers ...

    Authors: Kim Hoffman, Gillian Leichtling, Sarah Shin, Andrew Seaman, Tonhi Gailey, Hunter C. Spencer and P. Todd Korthuis
    Citation: Addiction Science & Clinical Practice 2025 20:10
    Content type: Research Published on:

  43. Unhealthy alcohol use, a spectrum of use inclusive of risky consumption and alcohol use disorder (AUD), is a leading cause of preventable death in the United States. Most people with unhealthy alcohol use do n...

    Authors: Kara M. Magane, Richard Saitz, Sarah Fielman, Marc R. LaRochelle, Christopher W. Shanahan, Christine A. Pace, Michael LaValley, Kaley Penington, Skylar Karzhevsky and Emily Hurstak
    Citation: Addiction Science & Clinical Practice 2025 20:9
    Content type: Study Protocol Published on:

  44. Buprenorphine (BUP) treatment has been successfully integrated into primary care and other general medical settings; however, potential BUP prescribers frequently report inadequate training and resources to pr...

    Authors: Mariya Masyukova, Benjamin T. Hayes, Teresa López-Castro and Aaron D. Fox
    Citation: Addiction Science & Clinical Practice 2025 20:8
    Content type: Research Published on:

  45. Medications for opioid use disorder (MOUD) are among the best tools available to combat the opioid epidemic. Yet, use of MOUD among people with opioid use disorder (OUD) remains low. Interventions to increase ...

    Authors: Nicholas C. Cardamone, Rebecca E. Stewart, Kyle M. Kampman and Steven C. Marcus
    Citation: Addiction Science & Clinical Practice 2025 20:7
    Content type: Research Published on:

  46. Initiation of buprenorphine for treatment of opioid use disorder (OUD) in acute care settings improves access and outcomes, however patients who use methamphetamine are less likely to link to ongoing treatment...

    Authors: Elenore P. Bhatraju, Devin N. Kennedy, Alexander J. Gojic, Matthew Iles-Shih, Joseph O. Merrill, Jeffrey H. Samet, Kevin A. Hallgren and Judith I. Tsui
    Citation: Addiction Science & Clinical Practice 2025 20:6
    Content type: Study Protocol Published on:

  47. Unhealthy alcohol use is an independent, modifiable risk factor for HIV, but limited research addresses alcohol use and HIV prevention synergistically. Groups that experience chronic stigma, discrimination, an...

    Authors: Olivia V. Fletcher, Kristine Beaver, Elizabeth J. Austin, Jenna van Draanen, E. Jennifer Edelman and Emily C. Williams
    Citation: Addiction Science & Clinical Practice 2025 20:5
    Content type: Research Published on:

  48. Women involved in the criminal legal system have elevated rates of opioid use disorder, which is treatable, and HIV, which is preventable with pre-exposure prophylaxis (PrEP). There are significant social and ...

    Authors: Jaimie P. Meyer, Stacey Brunson, Carolina R. Price, Morgan Mulrain, Julie Nguyen, Frederick L. Altice, Tassos C. Kyriakides, Karen Cropsey and Ellen Eaton
    Citation: Addiction Science & Clinical Practice 2025 20:4
    Content type: Study Protocol Published on:

  49. Opioid-related fatal overdoses are occurring at historically high levels and increasing each year. Accessible social and financial support are imperative to the initiation and success of treatment for Opioid U...

    Authors: Emily G. Hichborn, Owen B. Murray, Eilis I. Murphy, Tess E. Gallant, Sarah K. Moore, Bethany M. McLeman, John Saroyan, Anthony Folland, Megan Mitchell and Lisa A. Marsch
    Citation: Addiction Science & Clinical Practice 2025 20:3
    Content type: Research Published on:

  50. College students who are in recovery from substance use disorders face challenges related to abstaining from substance use, finding supportive social networks, and achieving their academic goals. These student...

    Authors: Lindsey M. Nichols, Tiffany B. Brown, Angela Allmendinger, Emily A. Hennessy and Emily E. Tanner-Smith
    Citation: Addiction Science & Clinical Practice 2025 20:2
    Content type: Research Published on:
Submit manuscript
  • New Content Item

Follow

Affiliated with

Annual Journal Metrics

  • Citation Impact 
    Journal Impact Factor: 3.7 (2023)    
    5-year Journal Impact Factor: 4.2 (2023)    
    Source Normalized Impact per Paper (SNIP): 0.848 (2024)    
    SCImago Journal Rank (SJR): 1.187 (2024)

    Speed 
    Submission to first editorial decision (median days): 17
    Submission to acceptance (median days): 250

    Usage 2024
    Downloads: 627,221
    Altmetric mentions: 247

Archival content

Addiction Science & Clinical Practice was formerly published by NIDA and previous issues of the journal can be viewed here.

Addiction Science & Clinical Practice

ISSN: 1940-0640